Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959709 | 0.87 | PDE5A (0.33) | SLC47A1 | |
| SCHEMBL6233939 | 0.85 | KIF11 (0.44) | — | |
| SCHEMBL6238476 | 0.83 | L3MBTL1 (0.41) | L3MBTL1CYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL3078710 | 0.81 | HTR2A (0.39) | L3MBTL1AOC3ALOX5APFEN1HTR2A | |
| SCHEMBL3081194 | 0.81 | AOC3 (0.43) | L3MBTL1AOC3ALOX5APFEN1HTR2A | |
| SCHEMBL7562211 | 0.80 | L3MBTL1 (0.40) | L3MBTL1CYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL3081098 | 0.79 | CYP2A6 (0.40) | AOC3ALOX5APFEN1HTR2A | |
| SCHEMBL3087081 | 0.78 | ALDH1A1 (0.38) | SLC47A1 | |
| SCHEMBL3360367 | 0.77 | KDM4E (0.33) | CYP2C19 | |
| SCHEMBL10741588 | 0.76 | L3MBTL1 (0.49) | L3MBTL1CYP1A2CYP2D6CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| EP-1392653-B1 | A SHORT SYNTHESIS OF PYRIDINE-BASED PHARMACEUTICAL INTERMEDIATES WITH SULFUR-CONTAINING GROUPS AT THE 2- AND 3-POSITIONS | UNIV NORTH CAROLINA STATE (US) | 2007-08-15 | — | — | EP | disclosed |
| US-6987189-B2 | Short synthesis of pyridine-based pharmaceutical intermediates | NORTH CAROLINA STATE UNIVERSITY (US) | 2006-01-17 | — | — | US | disclosed |
| US-20050065347-A1 | Short synthesis of pyridine-based pharmaceutical intermediates | COMINS DANIEL L (US) | 2005-03-24 | — | — | US | disclosed |
| US-6855825-B2 | Short synthesis of pyridine-based pharmaceutical intermediates | NORTH CAROLINA STATE UNIVERSITY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040138463-A1 | Short synthesis of pyridine-based pharmaceutical intermediates | COMINS DANIEL L (US) | 2004-07-15 | — | — | US | disclosed |
| US-6706884-B2 | REACTING 2-METHYL-3-(TERT-BUTYLTHIO)PYRIDINE DERIVATIVE WITH AMINOALKYL DISULFIDE DERIVATIVE; SULFIDING IN STRONG AMIDE BASE | NORTH CAROLINA STATE UNIVERSITY | 2004-03-16 | — | — | US | disclosed |
| US-20030166941-A1 | Short synthesis of pyridine-based pharmaceutical intermediates | COMINS DANIEL L (US) | 2003-09-04 | — | — | US | disclosed |
| US-6534656-B2 | Intermediates in manufacture of antibiotic compounds | NORTH CAROLINA STATE UNIVERSITY | 2003-03-18 | — | — | US | disclosed |
| US-20020193606-A1 | Short synthesis of pyridine-based pharmaceutical intermediates | NORTH CAROLINA STATE UNIVERSITY | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | L3MBTL1 304/4885CYP1A2 129/4885CYP2D6 399/4885 |
| US-20030166941-A1 | Short synthesis of pyridine-based pharmaceutical intermediates | CYP2B6, CYP2D6, CYP2A6 | L3MBTL1 4339/4885CYP1A2 23/4885CYP2D6 2/4885 |
| US-20040138463-A1 | Short synthesis of pyridine-based pharmaceutical intermediates | CYP2B6, CYP2D6, CYP2A6 | L3MBTL1 4339/4885CYP1A2 23/4885CYP2D6 2/4885 |
| US-20020193606-A1 | Short synthesis of pyridine-based pharmaceutical intermediates | CYP2B6, CYP2D6, CYP2A6 | L3MBTL1 4339/4885CYP1A2 23/4885CYP2D6 2/4885 |
| US-20050065347-A1 | Short synthesis of pyridine-based pharmaceutical intermediates | CYP2B6, CYP2D6, CYP2A6 | L3MBTL1 4314/4885CYP1A2 37/4885CYP2D6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.